Health ❯ Healthcare ❯ Clinical Trials

Cancer Research

Immunotherapy Lung Cancer Breast Cancer Glioblastoma Prostate Cancer Survival Rates Patient Outcomes Pancreatic Cancer Multiple Myeloma Melanoma Trials Small Cell Lung Cancer Therapeutic Innovations Personalized Medicine Solid Tumors Biliary Tract Cancer B-cell Acute Lymphoblastic Leukemia Myeloma Clinical Trials Immunocore PD-(L)1/VEGF Antibodies ECHELON-1 Trial Blood Cancers Leukaemia Trials Pembrolizumab Pancreatic Ductal Adenocarcinoma Intercept-Lynch Trial Innovative Treatments Antibody Development Car T-cell Therapy Immunotherapy Trials Melanoma Grail Innovative Therapies Allogeneic CAR T Cells Diffuse Large B-Cell Lymphoma Phase III Trials Tumor Targeting Leukemia UAE Medical Innovations HER2-positive Breast Cancer HER2-Mutation Therapies Head and Neck Cancer Targeted Therapy Therapeutic Techniques Lymphoma Treatments Study Findings Brexit Impact Pediatric Oncology Glioblastoma Treatment Hodgkin Lymphoma NHS-Galleri Trial Feline Cancer Treatments PIK3CA Mutations in Breast Cancer Ovarian Cancer Financial Barriers Skin Cancer Vaccines Cholangiocarcinoma Colorectal Cancer Esophageal Cancer Translational Oncology Diagnostic Innovations HER2 Positive Breast Cancer PCT Development Non-Small Cell Lung Cancer Daratumumab Studies Case Western Reserve University

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Approval by October 9, 2026 would establish the first immunotherapy-based adjuvant option for patients with dMMR/MSI-H stage III colon cancer.

Securities Suit Filed Against Grail After NHS‑Galleri Readout Misses Primary Endpoint

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

UCSF-Led Study Engineers CAR-T Cells In Vivo, Clearing Tumors in Mice

Ligand-Based OSM CAR-T Shows Preclinical Efficacy Against Osteosarcoma

Oncolytic Viruses Trigger T‑Cell Infiltration and Survival Signals in Early Glioblastoma Trials

Trials Show Fecal Transplants Enhance Cancer Immunotherapy, Including Longer PFS in Randomized Kidney Study

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Immunotherapy Before 3 p.m. Linked to Longer Survival in Small Cell Lung Cancer

City of Hope Completes $1.5 Billion Irvine Cancer Hospital, First Patients Arrive Dec. 1

Pluvicto Added to Standard Care Extends rPFS in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

Antibody Blocking SLAMF6 Restores T-Cell Attack on AML in Preclinical Study

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

Nature Papers Identify RHOG and CDKN1B as In Vivo Boosters for CAR T Cells

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

Kite Pharma to Buy Interius for $350 Million, Adding In‑Vivo CAR‑T Platform

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

UC San Diego Launches Clinical Trial of Sequenced Radiotherapy and Immunotherapy for Head and Neck Cancer

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial